Translesion synthesis (TLS) promotes DNA damage tolerance and contributes to chemotherapy resistance by enabling replication across damaged DNA templates. REV1, a central TLS regulator, is a potential therapeutic target to enhance the efficacy of genotoxic chemotherapy. Here, we investigated the therapeutic consequences of pharmacologic and genetic REV1 targeting in colorectal cancer (CRC) and evaluated the sensitivity of patient-derived CRC organoids to the REV1 inhibitor JH-RE-06. JH-RE-06 enhanced oxaliplatin sensitivity in HCT116 cells and 5-fluorouracil (5-FU) sensitivity in HT-29 cells, whereas reciprocal combinations produced limited sensitization, indicating treatment-and cellular context-dependent responses. siRNA-mediated REV1 depletion similarly enhanced chemotherapy sensitivity, supporting REV1 involvement in these responses. MNNG sensitivity assays and MLH1 expression analyses did not reveal consistent treatment-associated changes in mismatch repair function, while targeted HPRT1 sequencing identified no detectable sequence alterations in the region examined. Chemosensitization was not accompanied by consistent increases in caspase-3/7 activation under the conditions tested. REV1 inhibition also caused LC3-II accumulation and, after prolonged inhibitor exposure, reduced β-tubulin abundance, indicating additional autophagy-associated and cytoskeletal responses. In two patient-derived CRC organoid models, JH-RE-06 exhibited single-agent growth-inhibitory activity, with mean IC50 values of 2.01 and 1.4 µM, respectively. Together, these findings demonstrate context-dependent chemosensitization and organoid growth inhibition following REV1 targeting, suggesting that its therapeutic consequences may extend beyond canonical TLS-mediated DNA damage tolerance. SIGNIFICANCE STATEMENT: Targeting REV1 enhances sensitivity to specific chemotherapeutic agents in colorectal cancer cells and inhibits growth of patient-derived colorectal cancer organoids. REV1 inhibition is also accompanied by LC3-II accumulation and reduced β-tubulin abundance, revealing cellular responses beyond conventional measures of DNA damage and mutagenesis. These findings identify treatment-dependent therapeutic vulnerabilities and suggest that the consequences of REV1 targeting may extend beyond its established role in translesion synthesis, supporting further investigation of REV1-directed therapeutic strategies in colorectal cancer. CLINICAL TRANSLATION RELEVANCE: Chemotherapy resistance remains a major obstacle to effective treatment of colorectal cancer (CRC). This study identifies REV1 as a potential therapeutic target, showing that pharmacologic and genetic REV1 targeting enhances oxaliplatin sensitivity in HCT116 cells and 5-fluorouracil (5-FU) sensitivity in HT-29 cells, while reciprocal combinations show limited additional sensitization. Furthermore, patient-derived CRC organoids demonstrate single-agent sensitivity to REV1 inhibition at low-micromolar concentrations, supporting its activity across distinct tumor-derived models. REV1 inhibition is also associated with LC3-II accumulation and reduced β-tubulin abundance, suggesting additional cellular responses that may influence therapeutic outcomes. Together, these findings provide a preclinical rationale for investigating REV1-directed therapies in CRC and underscore the importance of identifying tumor-specific determinants of chemotherapy response and sensitivity to REV1 inhibition. Graphical Graphical abstract. Schematic representation of REV1 targeting and treatment-dependent chemosensitization in colorectal cancer Pharmacologic inhibition of REV1 using JH-RE-06 disrupts its interaction with polymerase ζ (POL ζ) and selectively enhances chemotherapy sensitivity in colorectal cancer (CRC) cells. REV1 inhibition increases sensitivity to 5-fluorouracil (5-FU) in mismatch repair-proficient (pMMR) HT-29 cells and to oxaliplatin in mismatch repair-deficient (dMMR) HCT116 cells, resulting in reduced clonogenic survival. REV1 inhibition is accompanied by increased LC3-II abundance and reduced β-tubulin expression, indicating autophagy-associated and cytoskeletal changes. Assays of mismatch repair-associated responses, HPRT mutagenesis, DNA damage, and apoptosis did not identify a consistent mechanism explaining the differential chemosensitization. JH-RE-06 also exhibits single-agent growth-inhibitory activity in patient-derived CRC organoids. Together, these findings highlight treatment-dependent therapeutic vulnerabilities associated with REV1 targeting in CRC.